Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2701 to 2715 of 9102 results

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development Reference number: GID-TA11235 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-HTG10870 Expected publication date:  15 October 2026

    HealthTech guidance
    In development

  3. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 7 July 2026.

    In consultation

  4. Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease

    Awaiting development Reference number: GID-TA12460 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Asciminib for untreated Philadelphia-chromosome-positive chronic myeloid leukaemia in the chronic phase

    Awaiting development Reference number: GID-TA12455 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development

  7. Teplizumab for delaying progression of stage 3 type 1 diabetes in people 8 years and over [TSID12403]

    Awaiting development Reference number: GID-TA12037 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]

    Awaiting development Reference number: GID-TA12469 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Glofitamab for treating relapsed or refractory mantle cell lymphoma

    Awaiting development Reference number: GID-TA12447 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    In development Reference number: GID-TA12518 Expected publication date:  07 April 2027

    Technology appraisal guidance
    In development

  12. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]

    In development Reference number: GID-TA11484 Expected publication date:  12 August 2026

    Technology appraisal guidance
    In development

  13. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-HTG10881 Expected publication date:  11 February 2027

    HealthTech guidance
    In development

  14. Garetosmab for preventing heterotopic ossification and flare ups associated with fibrodysplasia ossificans progressiva [ID3772]

    Awaiting development Reference number: GID-TA12522 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 23 July 2026.

    Technology appraisal guidance
    In consultation